Brief: Alx Oncology Announces First Patient Dosed In Phase 2 Investigator-Sponsored Trial Of Evorpacept In Patients With Ovarian Cancer
09/05/2023 12:27
May 9 (Reuters) - ALX Oncology Holdings Inc ALXO.O :
* ALX ONCOLOGY ANNOUNCES FIRST PATIENT DOSED IN PHASE 2
INVESTIGATOR-SPONSORED TRIAL OF EVORPACEPT IN PATIENTS WITH
OVARIAN CANCER
* ALX ONCOLOGY HOLDINGS INC - ALX ONCOLOGY OWNS WORLDWIDE
COMMERCIAL RIGHTS TO EVORPACEPT
Source text for Eikon: ID:nGNX42ttdn
Further company coverage: ALXO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ALX Oncology Holdings
See all newsALX Oncology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
ALX Oncology Holdings Inc expected to post a loss of 15 cents a share - Earnings Preview
ALX Oncology Q2 net loss narrows on lower R&D costs
Brief: ALX Oncology Q2 Basic EPS USD -0.13
Brief: Alx Oncology Holdings - Enters Loan And Security Agreement With HSBC Ventures On June 25, 2026 - SEC Filing